Insider Selling: Regulus Therapeutics Inc. (NASDAQ:RGLS) VP Sells 38,547 Shares of Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS) VP Christopher Ray Aker sold 38,547 shares of the business’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $48,569.22. Following the completion of the transaction, the vice president now owns 54,634 shares in the company, valued at approximately $68,838.84. The trade was a 41.37 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Regulus Therapeutics Trading Up 3.7 %

RGLS stock traded up $0.05 during trading on Wednesday, reaching $1.27. 283,082 shares of the stock were exchanged, compared to its average volume of 348,120. The firm’s 50 day moving average is $1.53 and its 200 day moving average is $1.59. The firm has a market cap of $83.19 million, a P/E ratio of -1.19 and a beta of 1.60. Regulus Therapeutics Inc. has a twelve month low of $1.08 and a twelve month high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). As a group, analysts predict that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Creative Planning bought a new stake in shares of Regulus Therapeutics during the third quarter worth about $26,000. SG Americas Securities LLC acquired a new position in Regulus Therapeutics during the 3rd quarter valued at about $33,000. Jane Street Group LLC bought a new position in shares of Regulus Therapeutics in the third quarter valued at approximately $46,000. JPMorgan Chase & Co. boosted its holdings in Regulus Therapeutics by 193.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock worth $124,000 after acquiring an additional 52,059 shares during the last quarter. Finally, Barclays PLC grew its stake in shares of Regulus Therapeutics by 285.2% in the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after acquiring an additional 62,549 shares in the last quarter. 92.38% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. StockNews.com raised Regulus Therapeutics to a “sell” rating in a research note on Tuesday, September 17th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research note on Monday, November 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Regulus Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $10.80.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.